Skip to main content
SpringerLink
Log in

Hepatic Carbohydrate Metabolism

  • Chapter
  • First Online:
Molecular Pathology of Liver Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 5))

Abstract

The liver plays a unique role in controlling carbohydrate metabolism by maintaining glucose concentrations in a normal range. This is achieved by a tightly regulated system of enzymes and kinases regulating either glucose breakdown, storage as glycogen, or synthesis in hepatocytes. This process is under the control of glucoregulatory mediators among which insulin plays a key role. The fact that insulin is secreted into the portal system, takes the same route as absorbed glucose, and that the liver eliminates a large portion of the portal insulin at the first pass highlights the role of the liver not only as glucose supply, but as a site of glucose uptake and storage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pagliassotti MJ, Cherrington AD. Regulation of net hepatic glucose uptake in vivo. Annu Rev Physiol. 1992;54:847–60.

    PubMed  CAS  Google Scholar 

  2. Radziuk J. Hepatic glycogen in humans. I. Direct formation after oral and intravenous glucose or after a 24-h fast. Am J Physiol. 1989;257(2 pt 1):E145–57.

    PubMed  CAS  Google Scholar 

  3. Pencek RR, James F, Lacy DB, et al. Interaction of insulin and prior exercise in control of hepatic metabolism of a glucose load. Diabetes. 2003;52(8):1897–903.

    PubMed  CAS  Google Scholar 

  4. Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res. 2001;56:219–37.

    PubMed  CAS  Google Scholar 

  5. Gardemann A, Strulik H, Jungermann K. A portal-arterial glucose concentration gradient as a signal for an insulin-dependent net glucose uptake in perfused rat liver. FEBS Lett. 1986;202(2):255–9.

    PubMed  CAS  Google Scholar 

  6. Stumpel F, Scholtka B, Jungermann K. Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat. Ann NY Acad Sci. 2000;915:111–6.

    PubMed  CAS  Google Scholar 

  7. Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab. 2006;290(1):E169–76.

    PubMed  CAS  Google Scholar 

  8. Valera A, Bosch F. Glucokinase expression in rat hepatoma cells induces glucose uptake and is rate limiting in glucose utilization. Eur J Biochem. 1994;222(2):533–9.

    PubMed  CAS  Google Scholar 

  9. Girard J, Ferre P, Foufelle F. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr. 1997;17:325–52.

    PubMed  CAS  Google Scholar 

  10. Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J. 1996;10(10):1213–8.

    PubMed  CAS  Google Scholar 

  11. Ferre T, Pujol A, Riu E, Bosch F, Valera A. Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci USA. 1996;93(14):7225–30.

    PubMed  CAS  Google Scholar 

  12. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ. Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells. Biochem Soc Trans. 2007;35(Pt 5):1208–10.

    PubMed  CAS  Google Scholar 

  13. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 2004;30(5):398–408.

    PubMed  CAS  Google Scholar 

  14. Dentin R, Benhamed F, Hainault I, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 2006;55(8):2159–70.

    PubMed  CAS  Google Scholar 

  15. Dentin R, Pegorier JP, Benhamed F, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279(19):20314–26.

    PubMed  CAS  Google Scholar 

  16. Giacca A, Fisher SJ, Shi ZQ, Gupta R, Lickley HL, Vranic M. Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest. 1992;90(5):1769–77.

    PubMed  CAS  Google Scholar 

  17. Lewis GF, Zinman B, Groenewoud Y, Vranic M, Giacca A. Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes. 1996;45(4):454–62.

    PubMed  CAS  Google Scholar 

  18. Ferrannini E, Galvan AQ, Gastaldelli A, et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest. 1999;29(10):842–52.

    PubMed  CAS  Google Scholar 

  19. Duong DT, Waltner-Law ME, Sears R, Sealy L, Granner DK. Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem. 2002;277(35):32234–42.

    PubMed  CAS  Google Scholar 

  20. Hall RK, Yamasaki T, Kucera T, Waltner-Law M, O’Brien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem. 2000;275(39):30169–75.

    PubMed  CAS  Google Scholar 

  21. O’Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev. 1996;76(4):1109–61.

    PubMed  Google Scholar 

  22. Lewis GF, Vranic M, Giacca A. Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans. Am J Physiol. 1998;275(1 pt 1):E177–86.

    PubMed  CAS  Google Scholar 

  23. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002;8(12):1376–82.

    PubMed  CAS  Google Scholar 

  24. Cherrington AD, Edgerton D, Sindelar DK. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia. 1998;41(9):987–96.

    PubMed  CAS  Google Scholar 

  25. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes. 1998;47(4):523–9.

    PubMed  CAS  Google Scholar 

  26. Edgerton DS, Lautz M, Scott M, et al. Insulin’s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116(2):521–7.

    PubMed  CAS  Google Scholar 

  27. Fisher SJ, Kahn CR. Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production. J Clin Invest. 2003;111(4):463–8.

    PubMed  CAS  Google Scholar 

  28. Okamoto H, Obici S, Accili D, Rossetti L. Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest. 2005;115(5):1314–22.

    PubMed  CAS  Google Scholar 

  29. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97.

    PubMed  CAS  Google Scholar 

  30. Buettner C, Patel R, Muse ED, et al. Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest. 2005;115(5):1306–13.

    PubMed  CAS  Google Scholar 

  31. Cherrington AD. The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest. 2005;115(5):1136–9.

    PubMed  CAS  Google Scholar 

  32. Girard J. Insulin’s effect on the liver: “direct or indirect?” continues to be the question. J Clin Invest. 2006;116(2):302–4.

    PubMed  CAS  Google Scholar 

  33. Jungermann K, Gardemann A, Beuers U, et al. Regulation of liver metabolism by the hepatic nerves. Adv Enzyme Regul. 1987;26:63–88.

    PubMed  CAS  Google Scholar 

  34. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005;1(1):53–61.

    PubMed  CAS  Google Scholar 

  35. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90(4):1323–7.

    PubMed  CAS  Google Scholar 

  36. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(1):106–10.

    PubMed  CAS  Google Scholar 

  37. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992;54:885–909.

    PubMed  CAS  Google Scholar 

  38. Christ B, Nath A, Bastian H, Jungermann K. Regulation of the expression of the phosphoenolpyruvate carboxykinase gene in cultured rat hepatocytes by glucagon and insulin. Eur J Biochem. 1988;178(2):373–9.

    PubMed  CAS  Google Scholar 

  39. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131–8.

    PubMed  CAS  Google Scholar 

  40. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550–5.

    PubMed  CAS  Google Scholar 

  41. Christ B, Yazici E, Nath A. Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes. Hepatology. 2000;31(2):461–8.

    PubMed  CAS  Google Scholar 

  42. Metzger S, Goldschmidt N, Barash V, et al. Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am J Physiol. 1997;273(2 pt 1):E262–7.

    PubMed  CAS  Google Scholar 

  43. Inoue H, Ogawa W, Ozaki M, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004;10(2):168–74.

    PubMed  CAS  Google Scholar 

  44. Sun Y, Liu S, Ferguson S, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem. 2002;277(26):23301–7.

    PubMed  CAS  Google Scholar 

  45. Trinh KY, O’Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem. 1998;273(47):31615–20.

    PubMed  CAS  Google Scholar 

  46. Barzilai N, Rossetti L. Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin. J Biol Chem. 1993;268(33):25019–25.

    PubMed  CAS  Google Scholar 

  47. Burchell A, Cain DI. Rat hepatic microsomal glucose-6-phosphatase protein levels are increased in streptozotocin-induced diabetes. Diabetologia. 1985;28(11):852–6.

    PubMed  CAS  Google Scholar 

  48. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice over-expressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 1994; 91(19):9151–4.

    PubMed  CAS  Google Scholar 

  49. Samuel VT, Beddow SA, Iwasaki T, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci USA. 2009;106(29):12121–6.

    PubMed  CAS  Google Scholar 

  50. Yakar S, Liu JL, Fernandez AM, et al. Liver-specific Igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes. 2001;50(5):1110–8.

    PubMed  CAS  Google Scholar 

  51. Fernandez AM, Kim JK, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 2001;15(15):1926–34.

    PubMed  CAS  Google Scholar 

  52. Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes. 2003;52(10):2483–9.

    PubMed  CAS  Google Scholar 

  53. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113(1):96–105.

    PubMed  CAS  Google Scholar 

  54. O’Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab. 2002;87(9):4356–60.

    PubMed  Google Scholar 

  55. Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14(5):794–8.

    CAS  Google Scholar 

  56. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166–70.

    PubMed  CAS  Google Scholar 

  57. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94(26): 14924–9.

    PubMed  CAS  Google Scholar 

  58. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001;276(44):41293–300.

    PubMed  CAS  Google Scholar 

  59. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112(1):83–90.

    PubMed  CAS  Google Scholar 

  60. Basu R, Basu A, Grudzien M, et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes. 2009;58(1):39–45.

    PubMed  CAS  Google Scholar 

  61. Paulsen SK, Pedersen SB, Jorgensen JO, et al. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab. 2006;91(3):1093–8.

    PubMed  CAS  Google Scholar 

  62. Thieringer R, Hermanowski-Vosatka A. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? Expert Rev Cardiovasc Ther. 2005;3(5):911–24.

    PubMed  CAS  Google Scholar 

  63. Wang M. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs. 2006;7(4):319–23.

    PubMed  CAS  Google Scholar 

  64. White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997;40 suppl 2:S2–17.

    PubMed  CAS  Google Scholar 

  65. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol. 2002;12(2):65–71.

    PubMed  CAS  Google Scholar 

  66. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15(12):2099–111.

    PubMed  CAS  Google Scholar 

  67. D’Alfonso R, Marini MA, Frittitta L, et al. Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(1):317–22.

    PubMed  Google Scholar 

  68. Suzuki R, Tobe K, Aoyama M, et al. Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(−/−) mice. J Biol Chem. 2004;279(24):25039–49.

    PubMed  CAS  Google Scholar 

  69. Dong X, Park S, Lin X, Copps K, Yi X, White MF. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest. 2006;116(1):101–14.

    PubMed  CAS  Google Scholar 

  70. Simmgen M, Knauf C, Lopez M, et al. Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice. Diabetologia. 2006;49(3):552–61.

    PubMed  CAS  Google Scholar 

  71. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396(6706):77–80.

    PubMed  CAS  Google Scholar 

  72. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277(2):1531–7.

    PubMed  CAS  Google Scholar 

  73. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581–91.

    PubMed  CAS  Google Scholar 

  74. Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005;280(6):4617–26.

    PubMed  CAS  Google Scholar 

  75. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752–61.

    PubMed  CAS  Google Scholar 

  76. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457–61.

    PubMed  Google Scholar 

  77. Ozawa K, Miyazaki M, Matsuhisa M, et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes. 2005;54(3):657–63.

    PubMed  CAS  Google Scholar 

  78. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944–8.

    PubMed  CAS  Google Scholar 

  79. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–6.

    PubMed  CAS  Google Scholar 

  80. Gao Z, Zhang X, Zuberi A, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004;18(8):2024–34.

    PubMed  CAS  Google Scholar 

  81. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277(52):50230–6.

    PubMed  CAS  Google Scholar 

  82. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I )(kappa) B/NF-(kappa) B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27 suppl 3:S49–52.

    PubMed  CAS  Google Scholar 

  83. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–90.

    PubMed  CAS  Google Scholar 

  84. Tremblay F, Brule S, Hee Um S, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA. 2007;104(35):14056–61.

    PubMed  CAS  Google Scholar 

  85. Krebs M, Brunmair B, Brehm A, et al. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007;56(6):1600–7.

    PubMed  CAS  Google Scholar 

  86. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes. 2008;57(4):945–57.

    PubMed  CAS  Google Scholar 

  87. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–9.

    PubMed  CAS  Google Scholar 

  88. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7):731–7.

    PubMed  CAS  Google Scholar 

  89. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90(6):3498–504.

    PubMed  CAS  Google Scholar 

  90. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40(1):46–54.

    PubMed  CAS  Google Scholar 

  91. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91–100.

    PubMed  CAS  Google Scholar 

  92. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54(1):117–21.

    PubMed  CAS  Google Scholar 

  93. Kaser S, Foger B, Waldenberger P, et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J Hepatol. 2000;33(6):902–6.

    PubMed  CAS  Google Scholar 

  94. Harle P, Straub RH. Leptin is a link between adipose tissue and inflammation. Ann NY Acad Sci. 2006;1069:454–62.

    PubMed  Google Scholar 

  95. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345–50.

    PubMed  CAS  Google Scholar 

  96. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005;42(6):1339–48.

    PubMed  CAS  Google Scholar 

  97. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37(2):206–13.

    PubMed  CAS  Google Scholar 

  98. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology. 1998;115(4):947–53.

    PubMed  CAS  Google Scholar 

  99. Nolte W, Wirtz M, Rossbach C, et al. TIPS implantation raises leptin levels in patients with liver cirrhosis. Exp Clin Endocrinol Diabetes. 2003;111(7):435–42.

    PubMed  CAS  Google Scholar 

  100. Liangpunsakul S, Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol. 2004;38(10):891–7.

    PubMed  CAS  Google Scholar 

  101. Bethanis SK, Theocharis SE. Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci. 2006;51:1685–96.

    PubMed  CAS  Google Scholar 

  102. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12.

    PubMed  CAS  Google Scholar 

  103. Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004;53(7):1671–9.

    PubMed  CAS  Google Scholar 

  104. Rangwala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes. 2004;53(8):1937–41.

    PubMed  CAS  Google Scholar 

  105. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111(2):225–30.

    PubMed  CAS  Google Scholar 

  106. Muse ED, Obici S, Bhanot S, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest. 2004;114(2):232–9.

    PubMed  CAS  Google Scholar 

  107. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2001;276(28):25651–3.

    PubMed  CAS  Google Scholar 

  108. Engeli S, Bohnke J, Feldpausch M, et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res. 2004;12(1):9–17.

    PubMed  CAS  Google Scholar 

  109. Patel K, Muir A, McHutchison JG, Patton HM. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. Am J Gastroenterol. 2003;98(5):952–5.

    PubMed  CAS  Google Scholar 

  110. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50(10):2199–202.

    PubMed  CAS  Google Scholar 

  111. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359(9300):46–7.

    PubMed  CAS  Google Scholar 

  112. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab. 2002;87(5):2407.

    PubMed  CAS  Google Scholar 

  113. Lin SY, Sheu WH, Chen WY, Lee FY, Huang CJ. Stimulated resistin expression in white adipose of rats with bile duct ligation-induced liver cirrhosis: relationship to cirrhotic hyperinsulinemia and increased tumor necrosis factor-alpha. Mol Cell Endocrinol. 2005;232(1–2):1–8.

    PubMed  CAS  Google Scholar 

  114. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol. 2006;101(6):1244–52.

    PubMed  CAS  Google Scholar 

  115. Bahr MJ, Ockenga J, Boker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab. 2006;291(2): E199–206.

    PubMed  CAS  Google Scholar 

  116. Pagano C, Soardo G, Pilon C, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006;91(3):1081–6.

    PubMed  CAS  Google Scholar 

  117. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249):665–8.

    PubMed  CAS  Google Scholar 

  118. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389(6651):610–4.

    PubMed  CAS  Google Scholar 

  119. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343–50.

    PubMed  CAS  Google Scholar 

  120. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847–50.

    PubMed  CAS  Google Scholar 

  121. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154–9.

    PubMed  CAS  Google Scholar 

  122. Andreozzi F, Laratta E, Cardellini M, et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes. 2006;55(7):2021–4.

    PubMed  CAS  Google Scholar 

  123. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab. 2005;289(2):E251–7.

    PubMed  CAS  Google Scholar 

  124. Weigert C, Hennige AM, Lehmann R, et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem. 2006;281(11):7060–7.

    PubMed  CAS  Google Scholar 

  125. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9(1):20–9.

    PubMed  CAS  Google Scholar 

  126. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287(1):E182–7.

    PubMed  Google Scholar 

  127. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8(1):75–9.

    PubMed  CAS  Google Scholar 

  128. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.

    PubMed  CAS  Google Scholar 

  129. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–50.

    PubMed  CAS  Google Scholar 

  130. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000.

    PubMed  CAS  Google Scholar 

  131. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes. 2003;52(10):2453–60.

    PubMed  CAS  Google Scholar 

  132. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes. 1991;40(11):1397–403.

    PubMed  CAS  Google Scholar 

  133. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA. 2001;98(13):7522–7.

    PubMed  CAS  Google Scholar 

  134. Friedman J. Fat in all the wrong places. Nature. 2002;415(6869):268–9.

    PubMed  CAS  Google Scholar 

  135. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31(3):430–4.

    PubMed  CAS  Google Scholar 

  136. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116(9):2464–72.

    PubMed  CAS  Google Scholar 

  137. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21(6):1135–9.

    PubMed  CAS  Google Scholar 

  138. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592–9.

    PubMed  CAS  Google Scholar 

  139. Mangia A, Schiavone G, Lezzi G, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. 1998;93(12):2363–7.

    PubMed  CAS  Google Scholar 

  140. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract. 2006;75:320–6.

    PubMed  Google Scholar 

  141. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695–704.

    PubMed  CAS  Google Scholar 

  142. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci. 2002;47(4):710–5.

    PubMed  Google Scholar 

  143. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.

    PubMed  CAS  Google Scholar 

  144. Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology. 2002;304(2):415–24.

    PubMed  CAS  Google Scholar 

  145. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384–92.

    PubMed  CAS  Google Scholar 

  146. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–508.

    PubMed  CAS  Google Scholar 

  147. Nothnagel E. Handbuch Spezielle Pathologie Therapie 7. A.Holder,Wien. Glycosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In: E. N, editor. Handbuch Spez. Path. Terap. Vol B and 7. Wien: A. Holder; 1898: pp. 38–49.

    Google Scholar 

  148. Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver. 1988;8(6):354–9.

    PubMed  CAS  Google Scholar 

  149. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis. 1970;3:371–407.

    PubMed  CAS  Google Scholar 

  150. Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3(1):33–40.

    PubMed  CAS  Google Scholar 

  151. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroen terol Hepatol. 2002;17(6):677–81.

    PubMed  Google Scholar 

  152. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20(1 pt 1):119–25.

    PubMed  CAS  Google Scholar 

  153. Vannini P, Forlani G, Marchesini G, Ciavarella A, Zoli M, Pisi E. The euglycemic clamp technique in patients with liver cirrhosis. Horm Metab Res. 1984;16(7):341–3.

    PubMed  CAS  Google Scholar 

  154. Muller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102(6):2033–41.

    PubMed  CAS  Google Scholar 

  155. Kruszynska Y, Williams N, Perry M, Home P. The relationship between insulin sensitivity and skeletal muscle enzyme activities in hepatic cirrhosis. Hepatology. 1988;8(6):1615–9.

    PubMed  CAS  Google Scholar 

  156. Taylor R, Heine RJ, Collins J, James OF, Alberti KG. Insulin action in cirrhosis. Hepatology. 1985;5(1):64–71.

    PubMed  CAS  Google Scholar 

  157. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes. 1995;103(2):63–74.

    PubMed  CAS  Google Scholar 

  158. Raddatz D, Nolte W, Rossbach C, et al. Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements. Exp Clin Endocrinol Diabetes. 2008;116(8):461–7.

    PubMed  CAS  Google Scholar 

  159. Rittig K, Peter A, Baltz KM, et al. The CCR2 promoter polymorphism T-960A, but not the serum MCP-1 level, is associated with endothelial function in prediabetic individuals. Atherosclerosis. 2008;198(2):338–46.

    PubMed  CAS  Google Scholar 

  160. Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology. 1991;14(1):103–11.

    PubMed  CAS  Google Scholar 

  161. Raddatz D, Rossbach C, Buchwald A, Scholz KH, Ramadori G, Nolte W. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Exp Clin Endocrinol Diabetes. 2005;113(5):268–74.

    PubMed  CAS  Google Scholar 

  162. Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology. 2000;31(3):694–703.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Endocrinology, University of Göttingen, Göttingen, Germany

    Dirk Raddatz

Authors
  1. Dirk Raddatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuliano Ramadori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Raddatz .

Editor information

Editors and Affiliations

  1. School of Medicine, Dept. Pathology, University of Pittsburgh, 200 Lothrop Street, S421-BST, Pittsburgh, 15261, Pennsylvania, USA

    Satdarshan P. S. Monga

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Raddatz, D., Ramadori, G. (2011). Hepatic Carbohydrate Metabolism. In: Monga, S. (eds) Molecular Pathology of Liver Diseases. Molecular Pathology Library, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7107-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7107-4_8

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-7106-7

  • Online ISBN: 978-1-4419-7107-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation